Jean-Jacques Kiladjian: Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Jean-Jacques Kiladjian, Consultant Hematologist and Head of the Clinical Investigation Center of Hospital Saint-Louis and Professor of Clinical Pharmacology at Paris Diderot University, shared a post on LinkedIn about a recent article he and his colleagues authored:
“Very happy to be co-first author for this study in NEJM Evidence that will clearly change the management of these very agressive diseases with FGFR1 rearrangements. Very rare and heterogeneous conditions, only an international effort could show the usefulness of pemigatinib to improve symptoms and survival of patients with myeloid/lymphoid neoplasms with 8p11 rearrangements resulting in FGFR1 activation.
And a nice editorial by Drs Vivian Oehler and Roland Walter.”
Title: Pemigatinib for Myeloid/Lymphoid Neoplasms with FGFR1 Rearrangement
Authors: Srdan Verstovsek, Jean-Jacques Kiladjian, Alessandro M. Vannucchi, Jay L. Patel, Alessandro Rambaldi, William E. Shomali, Stephen T. Oh, Kensuke Usuki, Claire N. Harrison, Ellen K. Ritchie, Luke P. Akard, Juan Carlos Hernández-Boluda, Françoise Huguet, Philomena Colucci, Huiling Zhen, Natalia Oliveira, Aidan Gilmartin, Cheryl Langford, Tracy I. George, Andreas Reiter, Jason Gotlib
Read the Full Article in NEJM Evidence.
More posts featuring Jean-Jacques Kiladjian on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023